Ozempic (Semaglutide) Dosing and Administration Guidelines
Initiation and Titration for Type 2 Diabetes
- Begin treatment with 0.25 mg subcutaneously once weekly for the first 4 weeks, then increase to 0.5 mg weekly; if glycemic targets remain unmet, escalation to 1 mg weekly is permitted after at least 4 weeks on the 0.5 mg dose. 1
- The 0.25 mg starter dose is not intended for therapeutic effect but serves to lessen early gastrointestinal adverse events; the therapeutic maintenance doses are 0.5 mg or 1 mg weekly. 2
Dose Escalation for Obesity Management
In adults with a BMI ≥ 30 kg/m² (or ≥ 27 kg/m² with weight‑related comorbidities), a stepwise weekly titration is recommended:
Week Range Weekly Dose 1‑4 0.25 mg 5‑8 0.5 mg 9‑12 1.0 mg 13‑16 1.7 mg ≥ 17 2.4 mg (maintenance)
Route, Frequency, and Injection Site
- Administer Ozempic by subcutaneous injection once weekly; the injection may be given at any time of day, with or without meals. 1
Renal Impairment Considerations
- No dose adjustment is required for any level of renal function, including eGFR 15‑29 mL/min/1.73 m², eGFR < 15 mL/min/1.73 m², and end‑stage renal disease. 4
- This lack of renal dose modification distinguishes semaglutide from other GLP‑1 receptor agonists that require adjustment or are contraindicated in advanced kidney disease. 1
Hepatic Impairment Considerations
- No dose adjustment is necessary in patients with hepatic impairment. 5
Flexible Titration for Tolerability
- Clinicians may adopt a slower, individualized titration schedule when patients experience gastrointestinal symptoms, delaying dose escalation until tolerance is achieved. 2
Missed Dose Management
- If ≤ 2 consecutive weekly doses are missed, resume the previously tolerated dose; consider lowering the next dose if tolerance was marginal. 2
- If ≥ 3 consecutive doses are missed, restart the titration schedule from the beginning. 2
Gastrointestinal Safety Profile
- Nausea occurs in approximately 40 % of treated adults, vomiting in about 16 %, and diarrhea at a comparable frequency; these events are dose‑dependent and usually transient, improving with gradual titration. 2
Contraindications
- Personal or family history of medullary thyroid carcinoma.
- Presence of multiple endocrine neoplasia type 2 (MEN 2).
- Known serious hypersensitivity to semaglutide.
Hypoglycemia Risk Management
- When combined with insulin or sulfonylureas, proactively reduce the doses of those agents to mitigate hypoglycemia risk. 6
- Semaglutide monotherapy carries minimal intrinsic hypoglycemia risk because its insulin‑secretory effect is glucose‑dependent. 2
Drug Interaction Alerts
- Do not co‑administer with other GLP‑1 receptor agonists or DPP‑4 inhibitors. 2
- Semaglutide may delay gastric emptying, potentially altering the absorption of oral medications that require rapid onset. 2
Evidence‑Based Recommendations for Semaglutide (Ozempic)
Weight Management Efficacy
- In adults with obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with weight‑related comorbidities), a stepwise titration to a 2.4 mg weekly maintenance dose produced a mean body‑weight reduction of 14.9 %–16.0 % after 68 weeks in the STEP trial program, a large randomized controlled trial. 7
Renal Impairment Dosing
Renal dosing: No dose adjustment of semaglutide is required for any level of renal impairment, including estimated glomerular filtration rates as low as 15 mL/min/1.73 m² and even end‑stage renal disease. This recommendation is supported by clinical evidence published in Mayo Clinic Proceedings (2022). 8
Distinction from other GLP‑1 receptor agonists: Unlike many other agents in the class, semaglutide does not require dose reduction or have contraindications in advanced kidney disease, providing a therapeutic advantage for patients with significant renal dysfunction. 8